Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials

Camilo Jimenez; Pia Burman; Roger Abs; David R. Clemmons; William M. Drake; Kent R. Hutson; Michael Messig; Michael O. Thorner; Peter J. Trainer; Robert F. Gagel

doi:10.1530/EJE-08-0205

Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials

Camilo Jimenez, Pia Burman, Roger Abs, David R. Clemmons, William M. Drake, Kent R. Hutson, Michael Messig, Michael O. Thorner, Peter J. Trainer, Robert F. Gagel

Research output: Contribution to journal › Article › peer-review

Abstract

Objective: We examined pituitary tumor volumes in patients treated with pegvisomant for 18 months or longer, and in whom the tumors were monitored for at least 3 years. We present details on 9 of 304 patients in clinical trials with pegvisomant who experienced tumor growth within the first year of treatment. Method: Magnetic resonance images prior to start of pegvisomant and at last follow-up were examined in 43 patients (14% of participating patients). Twenty-nine had received prior radiation therapy (18% of irradiated patients) and all but five received somatostatin analogs between periods of pegvisomant treatment. Results: At follow-up, the median tumor volume was 0.6 cc (range 0.0-19.7 cc), in comparison with 1.6 cc (0.0-19.7 cc) at baseline (P

Original language	English
Pages (from-to)	517-523
Number of pages	6
Journal	European Journal of Endocrinology
Volume	159
Issue number	5
DOIs	https://doi.org/10.1530/EJE-08-0205
Publication status	Published - Nov 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1530/EJE-08-0205

Cite this

@article{4efafaa11c4944fd82e36415893b6c12,

title = "Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials",

abstract = "Objective: We examined pituitary tumor volumes in patients treated with pegvisomant for 18 months or longer, and in whom the tumors were monitored for at least 3 years. We present details on 9 of 304 patients in clinical trials with pegvisomant who experienced tumor growth within the first year of treatment. Method: Magnetic resonance images prior to start of pegvisomant and at last follow-up were examined in 43 patients (14% of participating patients). Twenty-nine had received prior radiation therapy (18% of irradiated patients) and all but five received somatostatin analogs between periods of pegvisomant treatment. Results: At follow-up, the median tumor volume was 0.6 cc (range 0.0-19.7 cc), in comparison with 1.6 cc (0.0-19.7 cc) at baseline (P",

author = "Camilo Jimenez and Pia Burman and Roger Abs and Clemmons, {David R.} and Drake, {William M.} and Hutson, {Kent R.} and Michael Messig and Thorner, {Michael O.} and Trainer, {Peter J.} and Gagel, {Robert F.}",

year = "2008",

month = nov,

doi = "10.1530/EJE-08-0205",

language = "English",

volume = "159",

pages = "517--523",

journal = "European Journal of Endocrinology",

issn = "0804-4643",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials

AU - Jimenez, Camilo

AU - Burman, Pia

AU - Abs, Roger

AU - Clemmons, David R.

AU - Drake, William M.

AU - Hutson, Kent R.

AU - Messig, Michael

AU - Thorner, Michael O.

AU - Trainer, Peter J.

AU - Gagel, Robert F.

PY - 2008/11

Y1 - 2008/11

N2 - Objective: We examined pituitary tumor volumes in patients treated with pegvisomant for 18 months or longer, and in whom the tumors were monitored for at least 3 years. We present details on 9 of 304 patients in clinical trials with pegvisomant who experienced tumor growth within the first year of treatment. Method: Magnetic resonance images prior to start of pegvisomant and at last follow-up were examined in 43 patients (14% of participating patients). Twenty-nine had received prior radiation therapy (18% of irradiated patients) and all but five received somatostatin analogs between periods of pegvisomant treatment. Results: At follow-up, the median tumor volume was 0.6 cc (range 0.0-19.7 cc), in comparison with 1.6 cc (0.0-19.7 cc) at baseline (P

AB - Objective: We examined pituitary tumor volumes in patients treated with pegvisomant for 18 months or longer, and in whom the tumors were monitored for at least 3 years. We present details on 9 of 304 patients in clinical trials with pegvisomant who experienced tumor growth within the first year of treatment. Method: Magnetic resonance images prior to start of pegvisomant and at last follow-up were examined in 43 patients (14% of participating patients). Twenty-nine had received prior radiation therapy (18% of irradiated patients) and all but five received somatostatin analogs between periods of pegvisomant treatment. Results: At follow-up, the median tumor volume was 0.6 cc (range 0.0-19.7 cc), in comparison with 1.6 cc (0.0-19.7 cc) at baseline (P

U2 - 10.1530/EJE-08-0205

DO - 10.1530/EJE-08-0205

M3 - Article

C2 - 18708436

SN - 0804-4643

VL - 159

SP - 517

EP - 523

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

IS - 5

ER -

Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this